New research by PerkinElmer confirms that PD-L1 protein expression levels in human breast cancer cells can be quickly and accurately assessed directly with the AlphaLISA human PD-L1 assay.
Using a PerkinElmer Opera Phenix Imaging System and proprietary analytic algorithms, a team of Austrian scientists developed Pharmacoscopy, a method to rapidly screen existing drugs for potential use in cancer immunotherapy.
Cancer researchers are uncovering new insights using our Phenoptics™ Quantitative Pathology Research Solutions. In a lung cancer case study, Dr. Rimm uses this instrumentation to evaluate tumor infiltrating lymphocytes.
Cancer researchers are uncovering new insights using our Phenoptics™ Quantitative Pathology Research Solutions. In a breast cancer case study, Dr. Rimm uses this instrumentation in her immune-oncology research.
Research at Institut Pasteur de Lille using PerkinElmer’s Opera® High-Content Screening System and Acapella® Image Analysis Software contributes substantial new information to our understanding of M. tuberculosis.
Cancer researchers now can visualize more of a tumor than ever before using PerkinElmer’s Phenoptics Quantitative Pathology Research Solutions. In a melanoma case study, Dr. Tumeh uses this instrumentation to develop biomarkers in his cancer immunology research.
A new generation of high-content imaging systems such as the PerkinElmer Operetta CLS High Content Imaging System and Harmony High Content Imaging and Analysis Software are helping scientists to blaze new trails in cancer drug therapy.
Scientists at UCLA's David Geffen School of Medicine are working with bioluminescent, fluorescent, and positron emission tomography (PET) technologies to reduce infections in post-surgical orthopedic patients as well as fight against metabolic cancer.
PerkinElmer and University of Colorado scientists review the current state of high-content (3D) imaging technologies that are advancing rapidly in the biological and biochemical sectors.
Researchers offer evidence of the importance of epithelial-to-mesenchymal transition (EMT) in the progression of chronic kidney disease.
PerkinElmer's Phenoptics™ quantitative pathology research system helped researchers reveal a predictive biomarker for Merkel cell carcinoma.
Using TIBCO Spotfire® visualization tools, PerkinElmer demonstrates this analytical versatile software in the study of infectious diseases.
PerkinElmer-GIS Centre for Precision Oncology leverages genome expertise and leading edge imaging instrumentation to develop new cancer therapies.
In a medical first, UNC researchers engineer and record skin cells becoming cancer killers using PerkinElmer’s IVIS system.
Monash Institute of Pharmaceutical Sciences is working to develop an inhaled oxytocin treatment for PPH, excessive bleeding after childbirth that kills an estimated 140,000 women a year.
Researchers at the University of Oklahoma have discovered potent polyphenols in brown seaweed that target and prevent the spread of pancreatic cancer cells. Their research is a potential blueprint for fighting the most lethal form of cancer, saving thousands of lives each year.
Using a suite of PerkinElmer's analytical imaging instruments, Dementias Platform United Kingdom (DPUK) is taking a whole-body approach to early detection, better treatment, and prevention of neurodegenerative conditions including Parkinson’s Disease, Motor Neurone Diseases, Multiple Sclerosis, Huntington’s Disease, Creutzfeldt–Jakob Disease, and Alzheimer’s Disease.
Scientists morph stem cells into mini-brains to prove that the Zika virus causes massive brain cell death in fetuses.
Groundbreaking research using PerkinElmer's Vectra multispectral imaging platform may lead to new immunotherapy treatments for cancer.
Using high content cellular imaging to engineer new drug therapies to combat human diseases.